The effect of rosiglitazone on the expression of thrombogenic markers on leukocytes in type 2 diabetes mellitus

Physiological Research

Volumn 58, Issue 5, 2009, Pages 701-707

  Svobodova H ^a   Stulc T ^a   Kasalova Z ^a   Dolezalova R ^a   Marinov, I ^b   Capek P ^a   Ceska R ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Diabetes mellitus; Rosiglitazone; Thrombogenic markers

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; MEMBRANE PROTEIN; P SELECTIN LIGAND PROTEIN; P-SELECTIN LIGAND PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; UROKINASE RECEPTOR;

AGED; ARTICLE; DRUG POTENTIATION; FEMALE; HUMAN; LEUKOCYTE; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSIOLOGY; THROMBOCYTE; THROMBOSIS;

AGED; BIOLOGICAL MARKERS; BLOOD PLATELETS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LEUKOCYTES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PPAR GAMMA; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; THIAZOLIDINEDIONES; THROMBOSIS;

EID: 72649105693     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bansilal S, Farkouh ME, Fuster V, Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am J Cardiol 99: 6B-14B, 2007.
2. Casey RG, Joyce M, Roche-Nagle G, Cox D, Bouchier-Hayes DJ, Young male smokers have altered platelets and endothelium that precedes atherosclerosis. J Surg Res 116: 227-233, 2004.
3. Dunn EJ, Grant PJ, Type 2 diabetes: an atherothrombotic syndrome. Curr Mol Med 5: 323-332, 2005.
4. El-Remessy AB, Behzadian MA, Abou-Mohamed G, Franklin T, Caldwell RW, Caldwell RB, Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am J Pathol 162: 1995-2004, 2003.
5. Furman MI, Benoit SE, Barnard MR, Valeri CR, Borbone ML, Becker RC, Hechtman HB, Michelson AD, Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 31: 352-358, 1998.
6. Fuster V, Moreno PR, Fayad za, Corti R, Badimon JJ, Atherothrombosis and high-risk plaque: evolving concepts. J Am Coll Cardiol 46: 937-954, 2005.
7. Hsueh WA, Law RE, PPARγ and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol 21: 1891-1895, 2001.
8. Hu H, Li N, Yngen M, Ostenson CG, Wallén NH, Hjemdahl P, Enhanced leukocyte-platelet cross-talk in Type 1 diabetes mellitus: relationship to microangiopathy. J Thromb Haemost 2: 58-64, 2004.
9. Kenichi M, Masanobu M, Takehiko K, Shoko T, Akira F, Katsushige A, Takashi H, Yoshiyuki O, Shigeru K, Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting- enzyme inhibitor. J Lab Clin Med 144: 69-77, 2004.
10. Le Gat L, Gogat K, Bouquet C, Saint-Geniez M, Darland D, Van Den Berghe L, Marchant D, Provost A, Perricaudet M, Menasche M, ABITBOL M, In vivo adenovirus-mediated delivery of a uPA/uPAR antagonist reduces retinal neovascularisation in a mouse model of retinopathy. Gene Ther 10: 2098-2103, 2003.
11. Lehrke M, Lazar MA, The many faces of PPAR(. Cell 123: 993-999, 2005.
12. Mathis G, Rare earth cryptates and homogeneous fluoroimmunoassays with human sera. Clin Chem 39: 1953-1959, 1993.
13. Moreno PR, Fuster V, New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 44: 2293- 2300, 2004.
14. Nissen SE, Wolski K, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471, 2007.
15. Patel CB, de Lemos JA, Wyne KL, Mcguire DK, Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPAR gamma agonism. Diab Vasc Dis Res 3: 65-71, 2006.
16. Penn MS, Topol EJ, Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling. Circ Res 89: 1-2, 2001.
17. Ragno P, The urokinase receptor: a ligand or a receptor? Story of a sociable molecule. Cell Mol Life Sci 63: 1028- 1037, 2006.
18. Salame MY, Samani NJ, Masood I, Debono DP, Expression of the plasminogen activator system in the human vascular wall. Atherosclerosis 152: 19-28, 2000.
19. Sarma J, Laan CA, Alam S, Jha A, Fox KA, Dransfield I, Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 105: 2166-2171, 2002.
20. Steins MB, Padró T, Schwaenen C, Ruiz S, Mesters RM, Berdel WE, Kienast J, Overexpression of urokinase receptor and cell surface urokinase-type plasminogen activator in the human vessel wall with different types of atherosclerotic lesions. Blood Coagul Fibrinolysis 15: 383-391, 2004.
21. Stratmann B, Tschoepe D, Pathobiology and cell interactions of platelets in diabetes. Diab Vasc Dis Res 2: 16- 23, 2005.
22. Štulc T, Kasalová Z, Krejčí H, Doležalová R, Češka R, Effect of rosiglitazone on homocysteine and creatinine levels in patients with type 2 diabetes. Atherosclerosis 183: 367-368, 2005.